Equillium to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Equillium, Inc. (Nasdaq: EQ) announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Jason Keyes, the Chief Financial Officer, will discuss ongoing clinical programs targeting acute graft-versus-host disease, lupus/lupus nephritis, and uncontrolled asthma. Attendees can engage in one-on-one meetings with Equillium's leadership during the event. A webcast of the presentation will be accessible for 90 days on their website. Equillium specializes in developing treatments for severe autoimmune disorders.

LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on March 9, 2021 at 7 am EST.

Jason Keyes, Equillium’s chief financial officer will review the Company’s ongoing clinical programs in acute graft-versus-host disease, lupus/lupus nephritis and uncontrolled asthma. Mr. Keyes and other members of Equillium’s leadership team will be available for one-on-one meetings during the conference.

The webcast will be available for 90 days under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

Investor & Media Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
+1-619-302-4431
ir@equilliumbio.com

FAQ

What will Equillium present at the H.C. Wainwright Global Life Sciences Conference?

Equillium will discuss its ongoing clinical programs for acute graft-versus-host disease, lupus/lupus nephritis, and uncontrolled asthma.

When will Equillium's presentation be available?

The presentation will be available on March 9, 2021, at 7 am EST.

How can I access Equillium's presentation after the event?

The webcast will be available for 90 days on Equillium’s website under the Investors section.

Who is the CFO of Equillium?

The CFO of Equillium is Jason Keyes.

What diseases is Equillium focusing on with its treatment itolizumab?

Equillium is focusing on diseases like acute graft-versus-host disease, lupus/lupus nephritis, and uncontrolled asthma.